Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

David Mickey

Hospitalist Baton Rouge, LA Medical Doctor

NPI 1447710397 CMS profile 11315906

5000 Hennessy Blvd, Baton Rouge, LA 70808

Open in the dashboard

General payments

$6,239

149 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Mickey of Baton Rouge, LA is reported in the CMS Open Payments database as having received $6,239 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,252 58
2024 General $2,463 61
2023 General $1,524 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Mickey
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to David Mickey were reported at $2,252. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year David Mickey Hospitalist median Middle half National median
2019 $0 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $0 $70 $23–$167 $132
2022 $0 $85 $27–$174 $149
2023 $1,524 $89 $30–$191 $160
2024 $2,463 $95 $29–$204 $164
2025 $2,252 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $1,564 38 payments
  2. BioCryst US Sales Co., LLC $1,188 18 payments
  3. GlaxoSmithKline, LLC. $1,098 21 payments
  4. Regeneron Healthcare Solutions, Inc. $1,002 29 payments
  5. Amgen Inc. $297 8 payments
  6. Novartis Pharmaceuticals Corporation $161 6 payments
  7. CSL Behring $155 5 payments
  8. Pharming Healthcare, Inc. $135 2 payments
  9. BioCryst Pharmaceuticals, Inc. $131 1 payment
  10. FUJIFILM Medical Systems USA, Inc. $97 1 payment
  11. Other $412 20 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,550 146 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $500 1 payment
  3. Education $189 2 payments
Products named General payments · program years 2023–2025
  1. Orladeyo $1,209 18 payments
  2. FASENRA $676 20 payments
  3. TEZSPIRE $661 16 payments
  4. DUPIXENT Inflammation And Immunology $625 19 payments
  5. NUCALA $595 19 payments
  6. DUPIXENT Immunology And Inflammation $252 9 payments
  7. ACTIMMUNE $243 5 payments
  8. RUCONEST $135 2 payments
  9. AIRSUPRA $122 3 payments
  10. Hizentra $118 4 payments
  11. Other $741 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

135

Median for Hospitalist: 109

Drug cost

$2,940

Median for Hospitalist: $6,399

Branded share of claims

18.5%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 34 $1,129
Albuterol Sulfate Hfa Albuterol Sulfate Brand 25 $735
Fluticasone Propionate Generic 48 $685
Triamcinolone Acetonide Generic 12 $242
Ipratropium Bromide Generic 16 $148

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Orladeyo
  • BioCryst US Sales Co., LLC $705
$705 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $506
$506 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $334
  • Amgen Inc. $21
$355 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $264
$264 — —
NUCALA
  • GlaxoSmithKline, LLC. $153
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record